Treatment of Patients With Major Depressive Disorder With MK0869 - Full Text View

Purpose

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Condition	Intervention	Phase
Major Depressive Disorder	Drug: MK0869, aprepitant Drug: Comparator: placebo	Phase III

MedlinePlus related topics:

Depression

Drug Information available for:

Aprepitant

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Safety/Efficacy Study

Official Title:	A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder

Further study details as provided by Merck:

Primary Outcome Measures:

HAMD-17 total score at week 8. Tolerability.

Secondary Outcome Measures:

CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score.

Estimated Enrollment:	450
Study Start Date:	January 2002

Detailed Description:

The duration of treatment is 8 weeks.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Major depressive disorder

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00034944

Locations


United States, Connecticut
	Call for information
	New Britain, Connecticut, United States, 06050

United States, Florida
	Call for information
	Altamonte Springs, Florida, United States, 32701
	Call for information
	Miami, Florida, United States, 33161

United States, Louisiana
	Call for information
	Shreveport, Louisiana, United States, 71103

United States, Virginia
	Call for information
	Richmond, Virginia, United States, 23294

United States, Wisconsin
	Call for information
	Middleton, Wisconsin, United States, 53711-3415

Sponsors and Collaborators

Merck

More Information

Publications:

Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S. Lack of Efficacy of the Substance P (Neurokinin(1) Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder. Biol Psychiatry. 2005 Oct 21; [Epub ahead of print]

Study ID Numbers:	2006_403, Formally-22
First Received:	May 2, 2002
Last Updated:	July 18, 2006
ClinicalTrials.gov Identifier:	NCT00034944
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Depression

Mental Disorders

Mood Disorders

Depressive Disorder, Major

Depressive Disorder

Aprepitant

Behavioral Symptoms

Additional relevant MeSH terms:

Pathologic Processes

Disease

Autonomic Agents

Therapeutic Uses

Physiological Effects of Drugs

Gastrointestinal Agents

Antiemetics

Peripheral Nervous System Agents

Central Nervous System Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 24, 2008

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00034944